Publications

Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia  (2024)

Authors:
Tamellini, E; Sorio, M; Andreini, A; Tecchio, C; Nadali, G; Bernardelli, A; Ferrarini, I; Crosera, L; Vatteroni, A; Simio, C; Benedetti, F; Krampera, M; Tanasi, I
Title:
Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia
Year:
2024
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Language:
Inglese
Referee:
No
Name of journal:
Blood Cell Therapy
N° Volume:
7
Number or Folder:
3
Page numbers:
75-78
Keyword:
FLT3-inhibitors; acute myeloid leukemia; post-transplant relapse
Short description of contents:
: Early post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse in patients with acute myeloid leukemia (AML) has an almost invariably dismal prognosis. Recent studies have demonstrated that FLT3 inhibition enhances the graft-versus-leukemia effect in vitro and in vivo. Thus, FLT-3 inhibitors may be viable treatment options in this setting. Here, we report three patients with FLT3 and NPM1 mutated AML who relapsed early after allo-HSCT and were treated with gilteritinib (associated with donor lymphocyte Infusion in two patients) to achieve long-term remission without a second transplantation.
Product ID:
141588
Handle IRIS:
11562/1141666
Last Modified:
December 19, 2024
Bibliographic citation:
Tamellini, E; Sorio, M; Andreini, A; Tecchio, C; Nadali, G; Bernardelli, A; Ferrarini, I; Crosera, L; Vatteroni, A; Simio, C; Benedetti, F; Krampera, M; Tanasi, I, Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia «Blood Cell Therapy» , vol. 7 , n. 32024pp. 75-78

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<back
Share